title: Left ventricular geometry in patients with obstructive sleep apnea coexisting with treated systemic hypertension.
abstract: BACKGROUND
  Left ventricular (LV) hypertrophy is a common consequence of systemic hypertension (SH) and obstructive sleep apnea (OSA). However, little is known about the degree of LV involvement in patients with OSA coexisting with treated SH.
  
  
  OBJECTIVE
  Our study was designed in order to assess the prevalence of distinct types of LV geometry in treated hypertensive OSA patients.
  
  
  METHODS
  
  
  
  METHODS
  183 patients with treated SH were enrolled to the study. Group 1 consisted of 38 patients with newly-diagnosed OSA and ineffectively treated SH. The remaining 145 patients with effectively treated SH were divided into three groups: group 2 - 70 patients with newly-diagnosed OSA, group 3 - 31 patients with OSA treated with continuous positive airway pressure (CPAP), and group 4 - 44 patients without OSA. Overnight sleep studies and M-mode echocardiography were performed.
  
  
  RESULTS
  LV mass index did not differ between the study groups. Mean values of LV end-diastolic diameter (LVED) were 55.4 +/- 6.8 mm in group 1 and 53.6 +/- 6.9 mm in group 2 and were significantly increased in comparison to subjects treated with CPAP and controls (49.8 +/- 6.8 mm and 50.1 +/- 64.7 mm, respectively; p = 0.001). LVED correlated positively with the apnea-hypopnea index and desaturation index. LV eccentric hypertrophy was the commonest type of LV geometry in newly-diagnosed OSA patients.
  
  
  CONCLUSIONS
  The major finding of our study is the predominance of LV eccentric hypertrophy in newly-diagnosed OSA patients. We suggest that a relatively moderate degree of LV involvement in hypertensive OSA patients may depend on the cardioprotective effect of concomitant antihypertensive therapy, ameliorating OSA-dependent neurohumoral abnormalities.
authors.affiliation: Department of Internal Medicine, University School of Medicine, Lublin, Poland. misl@poczta.wprost.pl
authors.forename: Wojciech
authors.initials: W
authors.lastname: Myslinski
authors.forename: Hans-Werner
authors.initials: HW
authors.lastname: Duchna
authors.forename: Kurt
authors.initials: K
authors.lastname: Rasche
authors.forename: Manuel
authors.initials: M
authors.lastname: Dichmann
authors.forename: Jerzy
authors.initials: J
authors.lastname: Mosiewicz
authors.forename: Gerhard
authors.initials: G
authors.lastname: Schultze-Werninghaus
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000502:physiology; D004452:Echocardiography; D006352:Heart Ventricles / Q000000981:diagnostic imaging* / Q000503:physiopathology; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D012720:Severity of Illness Index; D020181:Sleep Apnea, Obstructive / Q000150:complications* / Q000000981:diagnostic imaging / Q000503:physiopathology; D013318:Stroke Volume / Q000502:physiology; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents